# Neratinib

## Nerlynx 40 mg (180 tablets/bot)

##### 臨採

| TAH Drug Code      | [**ONER**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ONER)                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, Extended adjuvant, early stage, HER2-positive, following adjuvant trastuzumab based therapy.                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common Dermatologic: Rash (18% ) Endocrine metabolic: Weight decreased (5% to 20% ) Gastrointestinal: Abdominal pain (36% ), Constipation (31% ), Decrease in appetite (12% to 35% ), Diarrhea (78% to 98% ), Indigestion (10% ), Nausea (43% to 53% ), Stomatitis (14% ), Vomiting (26% to 46% ) Hepatic: ALT/SGPT level raised (9% ), Aspartate aminotransferase serum level raised (7% ) Musculoskeletal: Spasm (11% ) Neurologic: Dizziness (14% ) Other: Fatigue (27% to 45% ) Serious Renal: Renal impairment (7% ) |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

